0000000000677151

AUTHOR

Mehdi Karoui

showing 4 related works from this author

Perioperative FOLFOX 4 Versus FOLFOX 4 Plus Cetuximab Versus Immediate Surgery for High-Risk Stage II and III Colon Cancers: A Phase II Multicenter R…

2020

BACKGROUND Perioperative chemotherapy has proven valuable in several tumors, but not in colon cancer (CC). OBJECTIVE The aim of this study was to evaluate the efficacy and safety of perioperative chemotherapy in patients with locally advanced nonmetastatic CC. METHODS This is a French multicenter randomized phase II trial in patients with resectable high-risk T3, T4, and/or N2 CC on baseline computed tomography (CT) scan. Patients were randomized to receive either 6 months of adjuvant FOLFOX after colectomy (control) or perioperative FOLFOX for 4 cycles before surgery and 8 cycles after (FOLFOX peri-op). In RAS wild-type patients, a third arm testing perioperative FOLFOX-cetuximab was added…

AdultMalemedicine.medical_specialtyOrganoplatinum CompoundsColorectal cancermedicine.medical_treatmentPopulationLeucovorinCetuximab03 medical and health sciences0302 clinical medicineFOLFOXAntineoplastic Combined Chemotherapy ProtocolsMedicineHumanseducationColectomyColectomyAgedNeoplasm StagingTumor Regression Gradeeducation.field_of_studybusiness.industryPerioperativeMiddle Agedmedicine.diseaseInterim analysisdigestive system diseasesNeoadjuvant Therapy3. Good healthSurgeryTolerability030220 oncology & carcinogenesisColonic Neoplasms030211 gastroenterology & hepatologySurgeryFemaleFluorouracilFrancebusinessTomography X-Ray Computedmedicine.drugAnnals of surgery
researchProduct

Does neoadjuvant FOLFOX chemotherapy improve the prognosis of high‐risk Stage II and III colon cancers? Three years' follow‐up results of the PRODIGE…

2021

International audience; Aim Neoadjuvant chemotherapy has proven valuable in locally advanced resectable colon cancer (CC) but its effect on oncological outcomes is uncertain. The aim of the present paper was to report 3-year oncological outcomes, representing the secondary endpoints of the PRODIGE 22 trial. Method PRODIGE 22 was a randomized multicentre phase II trial in high-risk T3, T4 and/or N2 CC patients on CT scan. Patients were randomized between 6 months of adjuvant FOLFOX (upfront surgery) or perioperative FOLFOX (four cycles before surgery and eight cycles after; FOLFOX perioperative). In wild-type RAS patients, a third arm testing perioperative FOLFOX-cetuximab was added. The pri…

Oncologymedicine.medical_specialtyOrganoplatinum CompoundsColorectal cancer[SDV]Life Sciences [q-bio]medicine.medical_treatmentPopulationLeucovorinsurvival03 medical and health sciences0302 clinical medicineFOLFOXInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointHumanseducationNeoplasm StagingColectomyeducation.field_of_studybusiness.industryHazard ratioGastroenterologyPerioperativecolectomyPrognosisInterim analysismedicine.diseaseNeoadjuvant Therapydigestive system diseasescolon cancerChemotherapy Adjuvant030220 oncology & carcinogenesisColonic Neoplasms030211 gastroenterology & hepatologyFluorouracilNeoplasm Recurrence Localbusinessneoadjuvant chemotherapyFollow-Up Studiesmedicine.drugColorectal Disease
researchProduct

Impact of laparoscopy on oncological outcomes after colectomy for stage III colon cancer: A post-hoc multivariate analysis from PETACC8 European rand…

2021

Abstract Background In colon cancer (CC), surgery remains the mainstay of treatment with curative intent. Despite several clinical trials comparing open and laparoscopic approaches, data on long-term outcomes for stage III CC are lacking. Methods This post-hoc analysis of the European PETACC8 randomized phase 3 trial included patients from 340 sites between December 2005 and November 2009, with long follow-up (median 7.56 years). Patients were randomly assigned to FOLFOX or FOLFOX+cetuximab after colonic resection. The surgical approach was left to the referring surgeon's discretion. Results Among 2555 patients included, 1796 (70.29%) were operated on by open surgery and 759 (29.71%) by lap…

MaleLaparoscopic surgerymedicine.medical_specialtyOrganoplatinum CompoundsColorectal cancermedicine.medical_treatmentLeucovorinCetuximabAntineoplastic AgentsDisease-Free Survivallaw.invention03 medical and health sciences0302 clinical medicineFOLFOXRandomized controlled triallawAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansStage (cooking)Propensity ScoreLaparoscopyColectomyAgedNeoplasm StagingColectomyHepatologymedicine.diagnostic_testbusiness.industryGastroenterologyPrognosismedicine.diseaseSurgeryEuropeSurvival RateClinical trialTreatment Outcome030220 oncology & carcinogenesisColonic NeoplasmsMultivariate AnalysisFemaleLaparoscopy030211 gastroenterology & hepatologyFluorouracilbusinessFollow-Up Studiesmedicine.drugDigestive and Liver Disease
researchProduct

SARS-CoV-2 infection and venous thromboembolism after surgery: an international prospective cohort study

2021

SARS-CoV-2 has been associated with an increased rate of venous thromboembolism in critically ill patients. Since surgical patients are already at higher risk of venous thromboembolism than general populations, this study aimed to determine if patients with peri-operative or prior SARS-CoV-2 were at further increased risk of venous thromboembolism. We conducted a planned sub-study and analysis from an international, multicentre, prospective cohort study of elective and emergency patients undergoing surgery during October 2020. Patients from all surgical specialties were included. The primary outcome measure was venous thromboembolism (pulmonary embolism or deep vein thrombosis) within 30 da…

Malepulmonary embolismInternationalitySettore MED/18 - CHIRURGIA GENERALEDeep veinVascular damage Radboud Institute for Health Sciences [Radboudumc 16]infectious diseasesCardiovascularSARS‐CoV‐2surgeryCOVID-19 ; SARS-CoV-2 ; deep vein thrombosis ; pulmonary embolism ; venous thromboembolismCohort StudiesPostoperative ComplicationsAnesthesiologyMedicine and Health SciencesProspective Studies610 Medicine & healthProspective cohort studyLung11 Medical and Health SciencesConfoundingHematologyMiddle AgedThrombosis17 Psychology and Cognitive SciencesCOVID-19; deep vein thrombosis; pulmonary embolism; SARS-CoV-2; venous thromboembolismPulmonary embolismCOVID-19; SARS-CoV-2; deep vein thrombosis; pulmonary embolism; venous thromboembolism.medicine.anatomical_structureCohortCOVID-19/complicationsPostoperative Complications/etiologyOriginal ArticleFemalePatient SafetyLife Sciences & BiomedicineCOVID-19; SARS-CoV-2; deep vein thrombosis; pulmonary embolism; venous thromboembolismHumanAdultmedicine.medical_specialtyAdolescentClinical Sciencesvenous thromboembolism610 Medicine & healthGlobalSurg CollaborativeVenous Thromboembolism/etiologydeep vein thrombosisNOCOVIDSurg CollaborativeYoung AdultMedicine General & InternalAge DistributionClinical ResearchCOVID‐19General & Internal MedicinemedicineHumansSex DistributionAgedScience & Technologybusiness.industrySARS-CoV-2PreventionNeurosciencesdeep vein thrombosiCOVID-19PneumoniaOdds ratioOriginal Articlesmedicine.diseaseSurgeryReconstructive and regenerative medicine Radboud Institute for Health Sciences [Radboudumc 10]Prospective StudieGood Health and Well BeingAnesthesiology and Pain MedicineHuman medicinePostoperative ComplicationCohort StudiebusinessVenous thromboembolism[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct